• SciBase announced a planned NIH-led study with the Swiss Institute of Allergy and Asthma Research to assess environmental exposure’s effects on skin.
• The THREAT study will use Nevisense as a primary outcome measure to evaluate those effects; findings remain prospective.
• A deeper collaboration with Castle Biosciences generated an additional order worth about SEK 5 million for another clinical study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202611120200BITN____UKPR__SV_20261111-BIT-8062-0) on November 12, 2026, and is solely responsible for the information contained therein.